PMGC Holdings shares are trading higher after the company announced its subsidiary NorthStrive Bioscience signed a licensing agreement amendment with MOA Life to speed up the timing and key development milestones for EL-32 and EL-22 human clinical development program. Also, the company reported a year-over-year expansion of its asset base.